PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of canjgastrohepCanadian Journal of Gastroenterology and Hepatology
 
Can J Gastroenterol Hepatol. 2017; 2017: 1323607.
Published online 2017 July 2. doi:  10.1155/2017/1323607
PMCID: PMC5511633

Corrigendum to “Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement”

In the article titled “Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement” [1], there was an error regarding the FRAX® tool, which should be clarified as follows.

The article notes: “The WHO has developed an absolute fracture risk assessment tool (‘FRAX') to estimate the 10-year fracture risk in all adults, which is based on the integration of femoral neck bone density, age and other important clinical risk factors [66].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010. Treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References

1. Fouda M. A., Khan A. A., Sultan M., Rios L. P., McAssey K., Armstrong D. Evaluation and management of skeletal health in celiac disease: position statement. Canadian Journal of Gastroenterology. 2012;26(11):819–829. doi: 10.1155/2012/823648. [PMC free article] [PubMed] [Cross Ref]
2. Ford N., Norris S. L., Hill S. R. Clarifying WHO’s position on the FRAX® tool for fracture prediction. Bulletin of the World Health Organization. 2016;94(12, article 862) doi: 10.2471/BLT.16.188532. [PMC free article] [PubMed] [Cross Ref]

Articles from Canadian Journal of Gastroenterology & Hepatology are provided here courtesy of Hindawi Limited